"National auxiliary drug catalog" officially announced! Fly or tiger?

On July 1, the national health and Health Commission issued the notice on printing and distributing the first batch of national key monitoring and rational drug use catalogue (chemical and biological products), giving the list of the first batch of drugs, which should correspond to the "national auxiliary drug catalogue" discussed earlier The following are the key contents of the notice: 1 Formulate the provincial and various medical institutions directory, and each provincial health administrative department forms and publishes the provincial key monitoring rational drug directory; all kinds of medical institutions at all levels form their own key monitoring rational drug directory on the basis of the provincial directory 2 Focus on monitoring the clinical application of the drugs in the catalog, formulate medication guidelines or technical specifications for the drugs included in the catalog, and clearly define the conditions and principles of clinical application In order to ensure rational drug use, measures such as ranking notification, rectification within a time limit and clearing out the drug supply catalogue of the agency shall be taken for the varieties with prominent unreasonable drug use problems 3 Strengthen the prescription management of drugs out of the catalog, strictly implement the prescription management measures and other relevant provisions, and reasonably select the drug varieties, drug delivery routes and dosage and issue the prescription according to the indications, disease diagnosis and treatment standard guidelines and the corresponding prescription authority specified in the drug manual 4 Strengthen the monitoring and performance evaluation of the clinical use of drugs Take the clinical use of drugs included in the catalog as the evaluation content of the medical institutions and their main principals, combine with the verification, evaluation and performance evaluation of the medical institutions, and publicize the evaluation results in a timely manner 5 The list of 20 chemical and biological products in the first batch of catalogue (the data of main production enterprises, sales, sales as a percentage of the total sales and market share of pharmaceutical enterprises are taken from the open data on the Internet) although the list published in the first batch only involves chemical and biological products, it is expected that there will be the second batch and the third batch of list soon, and the traditional Chinese medicine injection and some Chinese patent medicines will also be involved in the future The reason why there is no correlation between traditional Chinese medicine and traditional Chinese medicine is probably the national policy of protecting traditional Chinese medicine, which makes the country more cautious According to the current trend, it is estimated that there are 40-60 national restricted directories, and other "magic drugs" will be added with local directories by provinces, cities and medical institutions The policy of the state is an obvious window guidance In the future, there will be no more auxiliary drugs and no space for drug policy with therapeutic value This is a big signal In the future, there will be problems in the admittance of auxiliary drugs to public hospitals all over the country Hospitals that have not been admitted may not be able to enter, and those that have already entered will also be squeezed out! The boots of "national catalogue of auxiliary drugs" have finally landed, and many manufacturers involved will also face great challenges From the list of the first 20 varieties, we can see that the sales volume is large, there are many manufacturers (actually involving 7, 80 pharmaceutical companies), and the total amount is still very large! As a whole, strict control of auxiliary drugs has a great impact on domestic enterprises In fact, from the second half of 2018 to the first half of 2019, the growth rate of multinational enterprises is very obvious, with 20% growth everywhere, while the growth rate of the whole pharmaceutical market is only about 6%, so the life of domestic pharmaceutical enterprises is more difficult, rather than better! The core reason is that we can see a data, among all multinational enterprises, therapeutic products account for 77%, while domestic pharmaceutical enterprises only account for 37% That is to say, many domestic small and medium-sized enterprises, except for a few far sighted and innovative pharmaceutical enterprises, have actively and passively entered the intellectual property and production technology barriers, which are mainly driven by marketing In the field of auxiliary drugs, we will face structural adjustment this time! After the publication of the catalogue of auxiliary drugs, under the background of strict national control, hospitals and doctors will be strictly controlled in the use of prescription auxiliary drugs, especially the use of high-priced auxiliary drugs, so a large number of auxiliary drug manufacturers with high prices and huge sales scale will fall into the death cycle! However, the country will not want to kill them, and manufacturers with low-cost auxiliary drugs or better production capacity and cost control may also have a wave of opportunities, because in the new mode of centralized mining, many clinically necessary auxiliary drugs may have a return flow of products with high quality and low price to meet clinical needs Therefore, after the publication of the national catalogue of auxiliary drugs, there are both advantages and disadvantages for the pharmaceutical industry In particular, the larger the sales scale of the original auxiliary drugs, the more serious the injury is Then the pharmaceutical enterprises that rely on several "magic drugs" to earn a lot of money will face the cliff like sales collapse However, the large-scale innovative drug head enterprises will receive the dividend of the national "cage for birds" this time For the sake that the scale of the whole pharmaceutical market will be consistent with the GDP and maintain a growth rate of more than 6%, after a large number of auxiliary drugs are injured, at the same time, the products of multinational enterprises should follow up the price reduction After the centralized purchase and consistency evaluation, the country should implement domestic substitution, so the increase will turn more to therapeutic products and innovative drugs! "A chicken dies and a chicken crows", but in the face of the irreversible trend of cliff, a large number of domestic small and medium-sized pharmaceutical enterprises abandon themselves Instead, they will give up innovation and research and development, save costs, and use all kinds of money laundering methods to pay kickbacks to ensure market share Because in the face of death threat, all means are useless! So in order to ensure the medical reform, strictly control the implementation of auxiliary drugs and centralized purchase policies, and guarantee the escort and success, the key is actually "drug enterprise audit", which can penetrate, verify and supervise the marketing expenses of drug enterprises from the supply side! The result should be determined next month It depends on the determination of the country whether to shoot flies or tigers or together!